Search results for "Androgen"

showing 10 items of 326 documents

The association of serum androsterone glucuronide with inflammatory lesions in women with adult acne1

2002

Serum androsterone glucuronide (AoG) is a metabolite of circulating androgens under the influence of 5α-reductase activity and has been shown to be particularly elevated in women with acne. In this study, we wanted to evaluate changes in AoG before and after treatment with an oral contraceptive or placebo, and to assess whether changes correlated with the number and type of acne lesions. In order to accomplish these aims, we obtained sera from a completed prospective randomized trial, which was designed to assess the effectiveness of an oral contraceptive compared to placebo. Assessments were carried out in 56 women with moderate acne who were treated with Ortho Tri-Cyclen (norgestimate and…

medicine.medical_specialtyAndrosteroneAndrosterone glucuronidebusiness.industryEndocrinology Diabetes and MetabolismHyperandrogenismPlaceboNorgestimatemedicine.diseaseGastroenterologychemistry.chemical_compoundEndocrinologyEndocrinologyDehydroepiandrosterone sulfatechemistryInternal medicineEthinylestradiolmedicinebusinessAcnemedicine.drugJournal of Endocrinological Investigation
researchProduct

Serum androsterone conjugates differentiate between acne and hirsutism in hyperandrogenic women

1991

Objective To determine if among hyperandrogenic women acne may be differentiated from hirsutism by markers of peripheral androgen metabolism. Design Prospective outpatient study of 36 hyperandrogenic women and controls divided into groups based on the presence or absence of significant hirsutism and the presence or absence of moderate to severe acne. Serum levels of adrenal and ovarian derived androgens were elevated but similar in all patient groups. Interventions Measurement of serum androgens including metabolites of 5 α -reductase activity: 3 α -androstanediol glucuronide and sulfate and androsterone (A) glucuronide and sulfate. Results 3 α -androstanediol glucuronide and sulfate were e…

medicine.medical_specialtyAndrosteronebusiness.industrymedicine.drug_classHyperandrogenismObstetrics and Gynecologymedicine.diseaseAndrogenchemistry.chemical_compoundEndocrinologyReproductive MedicinechemistryInternal medicineMedicineSerum androgensbusinessGlucuronideAcnehirsutismAndrostanediol glucuronideFertility and Sterility
researchProduct

Steroid activities comparison of natural and food wrap compounds in human breast cancer cell lines

2004

Abstract In this study, we tested and compared the endocrine disruption activities of compounds in materials used to package foods (bisphenol A, bisphenol F, and bisphenol A diglycidylether BADGE) with natural molecules (genistein, apigenin, kaempferol, and tangeretin) in the human breast cancer cell lines MCF-7 (ER + ) and MDA-MB453 (AR + ; GR + ). Octylphenol was also chosen as a xenoestrogen reference. Two compounds had no estrogenic activity: BADGE and tangeretin. Genistein was the most active compound in the E-Screen assay with MCF-7, followed by octylphenol, bisphenol F, bisphenol A and apigenin, with kaempferol the least potent. All estrogenic compounds competed with 17β-estradiol fo…

medicine.medical_specialtyBisphenol A[SDV]Life Sciences [q-bio]medicine.medical_treatmentGenisteinAntineoplastic AgentsBreast NeoplasmsEndocrine SystemToxicologySteroid03 medical and health scienceschemistry.chemical_compoundTangeretin0302 clinical medicinePhenolsInternal medicineTumor Cells CulturedmedicineAnticarcinogenic AgentsHumansEstrogens Non-SteroidalApigeninBenzhydryl CompoundsKaempferolsComputingMilieux_MISCELLANEOUS030304 developmental biologyFlavonoids0303 health sciencesDose-Response Relationship DrugFood PackagingGeneral MedicineFlavonesGenistein3. Good health[SDV] Life Sciences [q-bio]XenoestrogenEndocrinologyReceptors EstrogenchemistryMCF-7Receptors Androgen030220 oncology & carcinogenesisApigeninCarcinogensEpoxy CompoundsFemaleKaempferolhormones hormone substitutes and hormone antagonistsFood Science
researchProduct

Human Prostate Cancer: A Direct Role for Oestrogens

2007

We have studied the response to oestrogen and expression of oestrogen receptors in responsive LNCaP and androgen non-responsive PC3 human prostate cancer cell lines. Growth of LNCaP cells is significantly stimulated by physiological concentrations of oestradiol; this growth increase appears to be comparable to that induced by either testosterone or dihydrotestosterone. In contrast, oestradiol significantly inhibits the proliferation of PC3 cells. We also present novel evidence for functional oestrogen binding in LNCaP cells. This evidence was first obtained by means of radioligand binding assays and was further corroborated using: (a) immunocytochemical analysis of oestrogen and progesteron…

medicine.medical_specialtyChemistrymedicine.drug_classurologic and male genital diseasesmedicine.diseaseAndrogenProstate cancerchemistry.chemical_compoundEndocrinologyInternal medicineDihydrotestosteroneLNCaPmedicineGrowth inhibitionskin and connective tissue diseasesReceptorTestosteroneTransforming growth factormedicine.drug
researchProduct

Anti-androgens for the treatment of hirsutism.

2002

Many alternatives exist for treating hirsutism. Based on an analysis of scientific literature and on the experiences of the author, the most common anti-androgen agents are discussed in this review. Androgen receptor blockers (cyproterone acetate, flutamide and spironolactone), 5 alpha-reductase inhibitors (finasteride) and androgen-suppressing agents (gonadotrophin-releasing hormone [GnRH] agonists, oestroprogestins, corticosteroids and insulin-sensitising agents) are evaluated and compared. The importance of diagnosis in choosing the most appropriate anti-androgen treatment is also discussed.

medicine.medical_specialtyCholestenone 5 alpha-ReductaseHirsutismAnti-Androgenurologic and male genital diseasesFlutamideGonadotropin-Releasing Hormonechemistry.chemical_compoundInternal medicineAndrogen Receptor AntagonistsMedicineHumansPharmacology (medical)Androgen Receptor AntagonistshirsutismPharmacologybusiness.industryCyproterone acetateAndrogen AntagonistsGeneral Medicinemedicine.diseaseAndrogen receptorEndocrinologyTreatment OutcomechemistrySpironolactoneFinasterideAndrogensFemalebusinessOxidoreductasesExpert opinion on investigational drugs
researchProduct

Genetic and environmental aspect of polycystic ovary syndrome.

2004

Polycystic ovary syndrome (PCOS) is a heterogeneous syndrome determined in most patients by the association of two main factors: hyperandrogenism and insulin resistance. These characters are probably independent of each other and seem to be inherited by several different mechanisms. In some patients homozygous gene alteration has been found but in most patients PCOS seems to be determined by the association of gene polymorphisms that are common in the general population but alone are unable to determine phenotypic consequences. Alteration of genes that regulate the initial steps of ovarian steroidogenesis is probably the main causal factor of hyperandrogenism. Insulin resistance may be the …

medicine.medical_specialtyEndocrinology Diabetes and MetabolismPopulationBiologyEatingEndocrinologyInsulin resistanceInternal medicineInsulin receptor substratemedicineHumansGenetic Predisposition to DiseaseObesityeducationGeneeducation.field_of_studyHyperandrogenismmedicine.diseaseObesityPhenotypePolycystic ovaryEndocrinologyFemaleInsulin ResistanceEnergy MetabolismHyperandrogenismPolycystic Ovary SyndromeJournal of endocrinological investigation
researchProduct

Diagnosis, phenotype, and prevalence of polycystic ovary syndrome.

2006

New diagnostic criteria for polycystic ovary syndrome (PCOS) suggested three main phenotypes: classic (hyperandrogenism and anovulation), ovulatory, and normoandrogenic. However, it is unclear whether the normoandrogenic phenotype actually represents PCOS. Overall, 6% to 8% of reproductive-aged women suffer from PCOS, making this disorder one of the most common endocrine abnormalities.

medicine.medical_specialtyHirsutismendocrine system diseasesPolycystic ovary syndrome anovulation hyperandrogenismThree main phenotypesBiologyAnovulationDiagnosis DifferentialEpidemiologymedicinePrevalenceEndocrine systemHumansCystGynecologyHyperandrogenismnutritional and metabolic diseasesObstetrics and Gynecologymedicine.diseasePolycystic ovaryPhenotypefemale genital diseases and pregnancy complicationsPhenotypeReproductive MedicineFemaleHyperandrogenismAnovulationPolycystic Ovary SyndromeFertility and sterility
researchProduct

Adverse Effects of Anabolic-Androgenic Steroids: A Literature Review

2021

Anabolic-androgenic steroids (AASs) are a large group of molecules including endogenously produced androgens, such as testosterone, as well as synthetically manufactured derivatives. AAS use is widespread due to their ability to improve muscle growth for aesthetic purposes and athletes’ performance, minimizing androgenic effects. AAS use is very popular and 1–3% of US inhabitants have been estimated to be AAS users. However, AASs have side effects, involving all organs, tissues and body functions, especially long-term toxicity involving the cardiovascular system and the reproductive system, thereby, their abuse is considered a public health issue. The aim of the proposed review is to highli…

medicine.medical_specialtyLeadership and Managementinjuryorgan damagelcsh:MedicineHealth InformaticsInjuryReviewanabolic androgenic steroidsBioinformaticschronic administration03 medical and health sciences0302 clinical medicineHealth Information ManagementmedicineAASstoxicity.Adverse effect030304 developmental biology0303 health sciencesbiologyToxicitybusiness.industryAthletesHealth PolicyPublic healthlcsh:RtoxicityTestosterone (patch)Organ damageAnabolic-Androgenic Steroidsbiology.organism_classificationAASChronic administrationEducational interventionsWhole bodybusinessLarge groupAnabolic androgenic steroid030217 neurology & neurosurgeryanabolic androgenic steroidHealthcare
researchProduct

Cardiovascular risk and events in polycystic ovary syndrome

2009

Young women with polycystic ovary syndrome (PCOS) present a high risk for cardiovascular disease because of the presence of abdominal obesity, insulin resistance and androgen excess. In addition, they present with endothelial dysfunction and early signs of atherosclerosis (increased carotid intima-media thickness and increased coronary calcium). However, the evidence of increased cardiovascular events during the postmenopausal age is relatively small, although some recent studies have indicated a slight increase in the severity of cardiovascular disease in women who had PCOS during their fertile age. The discrepancy between cardiovascular risk in young age and postmenopausal cardiovascular …

medicine.medical_specialtyPCOS Cardiovascular risk myocardial infarction stroke atherosclerosisSettore MED/09 - Medicina InternaDiseaseAndrogen ExcessSeverity of Illness IndexSettore MED/13 - EndocrinologiaInsulin resistanceRisk FactorsInternal medicinePrevalencemedicineHumansEndothelial dysfunctionAbdominal obesityEvidence-Based Medicinebusiness.industryHyperandrogenismObstetrics and GynecologyGeneral Medicinemedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareSettore MED/40 - Ginecologia E OstetriciaPolycystic ovaryPostmenopauseEndocrinologyPremenopauseCardiovascular DiseasesFemalemedicine.symptombusinessDyslipidemiaPolycystic Ovary SyndromeClimacteric
researchProduct

Not all women diagnosed with PCOS share the same cardiovascular risk profiles

2009

Although definitive and confirmatory data are lacking, women with polycystic ovary syndrome (PCOS) are considered to be at increased risk for cardiovascular and metabolic disease. In recent years, the diagnosis of PCOS has broadened considerably to result in several phenotypes. Here we review the evidence for cardiovascular and metabolic risks in PCOS in the classic disorder and the various phenotypes. We conclude that not all women with PCOS should be considered as being similar in terms of cardiovascular risk profiles.

medicine.medical_specialtyPCOS cardiovascular risk hyperandrogenism insulin resistance metabolic syndrome lipid profileendocrine system diseasesRisk profileSettore MED/13 - EndocrinologiaMetabolic DiseasesRisk FactorsInternal medicinemedicineHumansCystMetabolic diseaseVascular diseasebusiness.industrynutritional and metabolic diseasesObstetrics and Gynecologymedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareSettore MED/40 - Ginecologia E OstetriciaPolycystic ovaryObesityfemale genital diseases and pregnancy complicationsPhenotypeEndocrinologyIncreased riskReproductive MedicineCardiovascular DiseasesMetabolomeFemaleMetabolic syndromeHyperandrogenismbusinessPolycystic Ovary SyndromeFertility and Sterility
researchProduct